Table 2.

Association of SNPs with carbamazepine pharmacokinetic measures in epilepsy patients receiving carbamazepine treatment.

Gene	SNP ID	Associated allele	Half-life	Clearance l/h/kg	CBZ-E:CBZ	CBZ-diol: CBZ-E
CYP3A4	rs2740574 (A>G)	A		p = 0.027↑†* (all)
CYP3A5	rs776746 (A>G)	G	p = 0.037↑‡*
ABCB1	rs1128503 (C>T)	T		p = 0.036↑‡*
	rs4148739 (A>G)	G				p = 0.023↑‡*
	rs4148740 (T>C)	C				p = 0.026↑‡*
ABCC2	rs2273697 (G>A)	A		p = 0.047↑†*	p = 0.002↑†**
	rs3740066 (A>G)	A			p = 0.008↓†**
	rs4148386 (A>G)	A		p = 0.012↑‡*	p = 0.049↑‡*
EPHX1	rs1051740 (C>T)	T				p = 0.026↓‡*
NR1I2	rs2461817 (T>G)	G		p = 0.03↓‡*	p = 0.006↑** (all)
	rs7643645 (A>G)	G			p =0.04↑* (all)
	rs4688040 (G>T)	T			p =0.04↑* (all)
	rs3814055 (C>T)	T		p = 0.04↓‡*
UGT2B7	rs28365063 (A>G)	G		p = 0.004↑‡**

Each row represents a SNP and each column represents a phenotype.

All: combined cohort of 90 patients consists of both whites and African–Americans.

^*p < 0.05;

^**p < 0.01.

^†Association of SNPs with pharmacokinetic phenotype in African–American population.

^‡Association of an allele with pharmacokinetic phenotype in African–American population.

↓: Decreased levels; ↑: Increased levels; CBZ: Carbamazepine; CBZ-diol: Carbamazepine-10,11-trans dihydro-diol; CBZ-E: Carbamazepine 10-11 epoxide.